Levalbuterol has not been established to have therapeutic advantage over racemic albuterol
- 1 August 2002
- journal article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 110 (2) , 325-8
- https://doi.org/10.1067/mai.2002.126375
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Low-dose levalbuterol in children with asthma: Safety and efficacy in comparison with placebo and racemic albuterolJournal of Allergy and Clinical Immunology, 2001
- The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patientsJournal of Allergy and Clinical Immunology, 2001
- Bronchoprotective and bronchodilator effects of single doses of ( S )-salbutamol, ( R )-salbutamol and racemic salbutamol in patients with bronchial asthmaEuropean Journal of Clinical Pharmacology, 1999
- Tolerance to the bronchoprotective effect of β2 -agonists: Comparison of the enantiomers of salbutamol with racemic salbutamol and placeboJournal of Allergy and Clinical Immunology, 1999
- Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine.Thorax, 1997
- Pharmacokinetics and extrapulmonary beta 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers.Thorax, 1997